Sermorelin

About

Sermorelin is a synthetic peptide analog of human growth hormone-releasing hormone (GHRH), corresponding to its first 29 amino acids (GRF 1-29). Developed to stimulate the body's manufacture and release of growth hormone (GH), it was first approved by the FDA in 1997 (trade name Geref) for growth hormone deficiency in children and adults; that approval was discontinued in 2008 for commercial reasons unrelated to safety. Research has explored its use in GH regulation, body composition, and longevity contexts, often alongside other secretagogues.

Research Applications

• Growth-hormone regulation
• Body composition and muscle recovery
• Anti-aging

Mechanism of Action

Sermorelin binds the growth hormone-releasing hormone receptor of the anterior pituitary gland, stimulating the secretion of growth hormone.

Molecular Info

Class

Peptide

Structure

Analog of the first 29 amino acids of GHRH (GRF 1-29)

Target

Growth hormone-releasing hormone receptor of the anterior pituitary

Primary research areas

Growth hormone regulation, body composition, and aging

Dosing Guidance

Range

Research discussions commonly cite starting around 100-200 mcg per day, often combined with other growth hormone secretagogues such as ipamorelin.

Frequency

Commonly administered daily in the cited research discussions.

Timing

Research discussions note administration at night before bed or first thing in the morning, when endogenous GH levels are typically highest.

Cycle length

Longevity research discussions cite cycles of roughly three to six months.

Notes

These details are educational context only. Protocol values are examples and should not be treated as medical instructions.

Regulatory & Evidence Status

Evidence level

Limited long-term data; human evidence is limited and dosing varies across research contexts.

FDA status

Previously approved (Geref, 1997); approval discontinued in 2008 for commercial reasons.

WADA status

Prohibited.

Standard Sermorelin Protocol

Example calculation values using a 5 mg vial, 2 mL bacteriostatic water, and a 200 mcg target amount.

Vial

5 mg

Water

2 mL

Target

200 mcg

Syringe

U-100 · 100 units

These example values cover reconstitution math only; scheduling, route, and administration decisions are not included.